Phase III study of APF530 versus ondansetron with a neurokinin 1 antagonist plus corticosteroid in preventing highly emetogenic chemotherapy-induced nausea and vomiting: MAGIC trial.

被引：15
|
作者：
Schnadig, Ian D.
Agajanian, Richy
Dakhil, Shaker R.
Gabrail, Nashat Y.
Smith, Robert E.
Taylor, Charles W.
Wilks, Sharon
Cooper, William
Mosier, Michael
Payne, Yvette
Klepper, Michael
Vacirca, Jeffrey L.
机构：
[1] US Oncol Network, Compass Oncol, Tualatin, OR USA
[2] Oncol Inst Hope & Innovat, Whittier, CA USA
[3] Canc Ctr Kansas, Wichita, KS USA
[4] Gabrail Canc Ctr, Canton, OH USA
[5] South Carolina Oncol Associates, Columbia, SC USA
[6] Tulsa Canc Inst, Tulsa, OK USA
[7] Canc Care Ctr South Texas, San Antonio, TX USA
[8] TFS Int, Flemington, NJ USA
[9] EMB Stat Solut LLC, Overland Pk, KS USA
[10] Heron Therapeut Inc, San Diego, CA USA
[11] Drug Safety Navigator LLC, Durham, NC USA
[12] North Shore Hematol Oncol, East Setauket, NY USA
来源：
JOURNAL OF CLINICAL ONCOLOGY | 2015年 / 33卷 / 28期
关键词：
D O I：
10.1200/jco.2015.33.28_suppl.68
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
68
引用
收藏
页数：1
相关论文
共 50 条
  • [21] A MULTI-CYCLE PHASE III STUDY EVALUATING PALONOSETRON VERSUS ONDANSETRON AT PREVENTING CHEMOTHERAPY-INDUCED NAUSEA AND VOMITING IN PEDIATRIC PATIENTS RECEIVING
    Kovacs, G.
    Wachtel, A.
    Basharova, E.
    Spinelli, T.
    Nicolas, P.
    Kabickova, E.
    PEDIATRIC BLOOD & CANCER, 2015, 62 : S167 - S167
  • [22] Randomized, Double-Blind, Phase III Study of Fosnetupitant Versus Fosaprepitant for Prevention of Highly Emetogenic Chemotherapy-Induced Nausea and Vomiting: CONSOLE
    Hata, Akito
    Okamoto, Isamu
    Inui, Naoki
    Okada, Morihito
    Morise, Masahiro
    Akiyoshi, Kohei
    Takeda, Masayuki
    Watanabe, Yasutaka
    Sugawara, Shunichi
    Shinagawa, Naofumi
    Kubota, Kaoru
    Saeki, Toshiaki
    Tamura, Tomohide
    JOURNAL OF CLINICAL ONCOLOGY, 2022, 40 (02) : 180 - +
  • [23] Phase III Trial of Casopitant, a Novel Neurokinin-1 Receptor Antagonist, for the Prevention of Nausea and Vomiting in Patients Receiving Moderately Emetogenic Chemotherapy
    Herrstedt, Jorn
    Apornwirat, Wichit
    Shaharyar, Ahmed
    Aziz, Zeba
    Roila, Fausto
    Van Belle, Simon
    Russo, Mark W.
    Levin, Jeremey
    Ranganathan, Salabha
    Guckert, Mary
    Grunberg, Steven M.
    JOURNAL OF CLINICAL ONCOLOGY, 2009, 27 (32) : 5363 - 5369
  • [24] Efficacy of thalidomide, neurokinin-1 receptor antagonist, and olanzapine in combination with palonosetron plus dexamethasone in preventing chemotherapy-induced nausea and vomiting (CINV) induced by highly emetogenic chemotherapy (HEC): Bayesian network meta-analysis
    Alhifany, Abdullah
    McBride, Ali
    Almutairi, Abdulaali
    Babiker, Hani M.
    MacDonald, Karen
    Abraham, Ivo
    JOURNAL OF CLINICAL ONCOLOGY, 2018, 36 (15)
  • [25] Phase III study of palonosetron for preventing chemotherapy-induced nausea and vomiting in pediatric patients
    Koga, Yuhki
    Kosaka, Yoshiyuki
    Koh, Katsuyoshi
    Matsumoto, Kimikazu
    Kumamoto, Tadashi
    Fujisaki, Hiroyuki
    Ishida, Yuji
    Suzuki, Ryoko
    Mochizuki, Shinji
    Goto, Hiroaki
    Yuza, Yuki
    Hara, Junichi
    ANNALS OF ONCOLOGY, 2021, 32 : S284 - S284
  • [26] Phase II clinical trial overview of the novel neurokinin-1 (NK-1) antagonist, casopitant, for the prevention of chemotherapy-induced nausea and vomiting (CINV) in patients receiving moderately and highly emetogenic chemotherapy
    Rogers, Miriam
    Pence, Christine
    Russo, Mark
    ONCOLOGY NURSING FORUM, 2008, 35 (03) : 557 - 557
  • [27] Slow-release granisetron (APF530) versus palonosetron for chemotherapy-induced nausea/vomiting: analysis by American Society of Clinical Oncology emetogenicity criteria
    Raftopoulos, Harry
    Boccia, Ralph
    Cooper, William
    O'Boyle, Erin
    Gralla, Richard J.
    FUTURE ONCOLOGY, 2015, 11 (18) : 2541 - 2551
  • [28] Randomized phase II trial of the neurokinin-1 receptor antagonist (NK-1 RA) casopitant mesylate with ondansetron (ond)/dexamethasone (dex) for chemotherapy-induced nausea/vomiting (CINV) in patients (pts) receiving highly emetogenic chemotherapy (HEC).
    Rolski, J.
    Ramlau, R.
    Dediu, M.
    Russo, M. W.
    Ross, G. A.
    Mather, R. A.
    Bandekar, R. R.
    Grunberg, S. M.
    JOURNAL OF CLINICAL ONCOLOGY, 2006, 24 (18) : 471S - 471S
  • [29] ANALYSIS OF PALONOSETRON VS ONDANSETRON IN PREVENTING CHEMOTHERAPY-INDUCED NAUSEA AND VOMITING (CINV) IN PEDIATRIC PATIENTS RECEIVING MODERATELY OR HIGHLY EMETOGENIC CHEMOTHERAPY (MEC/HEC)
    Kovacs, G.
    Wachtel, A. E.
    Basharova, E. V.
    Spinelli, T.
    Nicolas, P.
    Kabickova, E.
    PEDIATRIC BLOOD & CANCER, 2014, 61 : S108 - S108
  • [30] A prospective, randomized, double-blind phase 3 trial of extended-release granisetron (APF530) versus palonosetron (PALO) for preventing chemotherapy-induced nausea and vomiting (CINV) associated with moderately (MEC) or highly (HEC) emetogenic chemotherapy: Does a reanalysis using newer ASCO emetogenicity criteria affect study conclusions?
    Raftopoulos, Harry
    Boccia, Ralph V.
    Cooper, William
    O'Boyle, Erin
    Gralla, Richard J.
    JOURNAL OF CLINICAL ONCOLOGY, 2014, 32 (15)
12345